secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2022-01-06T23:59:59+00:00
Accession:  0001104659-22-001950
Event type: other_material
Sentiment:  positive
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hepion's lead NASH drug gets USAN name 'rencofilstat'
-----------------------------------------------------

- USAN Council adopted 'rencofilstat' as nonproprietary name for CRV431, Hepion's lead NASH/liver disease drug.
- The name will be used in future publications, conferences, and clinical development steps.
- Hepion is a clinical-stage biopharma focusing on AI-driven therapies for NASH and other liver diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000110465922001950/0001104659-22-001950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000110465922001950/tm221986d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-001950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer